Site Search
-
News Posted on Wed, 11/29/2023 -
News Posted on Wed, 07/21/2021 -
News Posted on Wed, 08/18/2021 -
News Posted on Wed, 04/15/2020 -
News Posted on Fri, 05/15/2020 -
News Posted on Fri, 08/16/2019 -
News Posted on Thu, 01/09/2020 -
News Posted on Thu, 01/09/2020 -
News Posted on Tue, 03/30/2021 -
News Posted on Thu, 09/03/2020 -
News Posted on Mon, 04/23/2018 -
News Posted on Thu, 04/15/2021 -
News Posted on Tue, 09/22/2020 -
News Posted on Tue, 09/10/2019 -
News Posted on Fri, 04/12/2019 -
CCR Online Magazine Article Reining in Rogue Immune Cells
A life-saving hematopoietic stem cell transplant, which replaces cancerous cells with a healthy immune system, allows many patients diagnosed with certain blood cancers to live for years with their cancer in remission. However, the treatment is not without side effects.
-
Staff Profile -
Staff Profile Xue Zhi Zhao, Ph.D.
Dr. Zhao has been a pioneer in the field of anti-AIDS agents, with a particular focus on developing inhibitors of HIV-1 integrase (IN). His recent studies have concentrated on the discovery of inhibitors that retain efficacy against virus harboring mutant forms of IN integrase, which are resistant to current FDA-approved drugs. These efforts are being done in collaboration with the NCI laboratories of Drs. Yves Pommier (Developmental Therapeutics Branch) and Stephen Hughes (HIV Drug Resistance Program).
-
CCR Online Magazine Article Once Infamous, Now Beneficial
First marketed in the late 1950s, thalidomide was widely prescribed to pregnant woman as a sedative to relieve morning sickness until tragedy struck.
-
CCR Online Magazine Article Moxe for Leukemia
The U.S. Food and Drug Administration’s (FDA) approval of moxetumomab pasudotox (Lumoxiti) in September 2018 for certain adults with hairy cell leukemia (HCL) provides a promising new therapy to a group of patients who previously had few other options.